SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 7, 2015
Aerie Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
2030 Main Street, Suite 1500
Irvine, California 92614
(Address of principal executive offices) (Zip code)
Registrants telephone number, including area code: (949) 526-8700
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
|Item 5.02||Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.|
(d) On May 7, 2015, the Board of Directors (the Board) of Aerie Pharmaceuticals, Inc. (the Company) appointed Richard Croarkin to the Board, effective immediately.
Mr. Croarkin was elected to serve as a Class III director for the duration of the Class III three-year term, which will expire at the annual meeting of stockholders to be held in 2016, or until the election and qualification of his successor. In addition, the Board elected Mr. Croarkin to serve on the Audit Committee. The Board has determined that Mr. Croarkin satisfies the definition of independent director and the requirements for service on the Audit Committee under the securities laws and NASDAQ listing standards.
Mr. Croarkin will receive compensation for his services in accordance with the Companys Non-Employee Director Compensation Program, under which he will receive a pro-rated annual retainer of $35,000 and a pro-rated annual committee fee of $9,000 for his services as a non-employee director and a member of the Audit Committee, respectively. In addition, Mr. Croarkin will be eligible to receive a one-time initial option award to purchase 25,000 shares of common stock of the Company, which will vest quarterly over a three-year period, subject to his continued service on the Board through each applicable vesting date.
There are no related party transactions reportable under Item 5.02(d)(4) of Form 8-K and Item 404(a) of Regulation S-K.
On May 7, 2015, the Company issued a press release announcing the appointment of Mr. Croarkin to the Board and election to the Audit Committee. A copy of the press release is furnished as Exhibit 99.1 hereto and is hereby incorporated by reference into this Item 5.02.
Item 9.01. Financial Statements and Exhibits.
The following exhibit relating to Item 5.02 shall be deemed to be furnished, and not filed:
99.1 Press Release dated May 7, 2015.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|AERIE PHARMACEUTICALS, INC.|
|Date: May 11, 2015||By:|| |
/s/ Richard J. Rubino
|Richard J. Rubino|
|Chief Financial Officer|
|99.1||Press Release dated May 7, 2015.|